Source: Virtual Congress 2020 – Intercellular communication in tissue remodelling of chronic lung diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Gotera (Madrid, Spain), A. Pereira Vega (Huelva, Spain), T. García Barrera (Huelva, Spain), J. Marín Trigo (Zaragoza, Spain), C. Casanova Macario (Santa Cruz De Tenerife., Spain), B. García-Cosío Piqueras (Palma de Mallorca, Spain), I. Mir Viladrich (Palma de Mallorca, Spain), I. Solanes García (Barcelona, Spain), J. Gómez Ariza (Huelva, Spain), J. López Campos (Sevilla, Spain), L. Seijo Maceiras (Madrid, Spain), N. Feu Collado (Córdoba, Spain), C. Cabrera López (Las Palmas De Gran Canarias, Spain), C. Amado Diago (Santander, Spain), A. Romero Plaza (Manacor, Spain), J. De Torres Tajes (Pamplona, Spain), L. Padrón Fraysse (Huelva, Spain), E. Márquez Martín (Sevilla, Spain), M. Marín Royo (Castellón., Spain), E. Balcells Vilarnau (Barcelona, Spain), A. Llunell Casanovas (Barcelona, Spain), C. Martínez González (Oviedo, Spain), J. Galdiz Iturri (Baracaldo, Spain), C. Lacárcel Bautista (Jaén, Spain), S. García Garrido (Huelva, Spain), G. Peces-Barba (Madrid, Spain). Biomarkers to predict FEV1 decline in smokers and early-onset COPD.. 2712

Member's Comments

No comment yet.

Related content which might interest you: The evaluation of different factors that cause FEV1 decline in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 135s Year: 2001 Frequent exacerbations in ex smokers with COPD are associated with accelerated rate of FEV1 decline Source: Eur Respir J 2005; 26: Suppl. 49, 510s Year: 2005 Which markers other than FEV1 reflect disease progression in COPD? Source: Eur Respir J 2004; 24: Suppl. 48, 45s Year: 2004 Does Smoking Cessation affect symptoms and FEV1 in smokers with mild COPD? Source: Virtual Congress 2020 – Smoking disease landscape: from inflammation to lung function and comorbidities Year: 2020 Comparison of spirometric z-scores with FEV1 percent prediction in predicting exacerbations in elderly COPD patients Source: International Congress 2016 – In-patient and out-patient COPD management Year: 2016 FEV1/Height2 could be a better alternative than FEV1 in predicting all cause mortality in patients with COPD Source: Annual Congress 2008 - COPD - clinical and epidemiological aspects Year: 2008 Frequent exacerbations in COPD are associated with accelerated rate of FEV1 decline Source: Eur Respir J 2006; 28: Suppl. 50, 32s Year: 2006 Reduced FEV3/FVC identifies smokers at risk of developing COPD in the SPIROMICS cohort Source: International Congress 2018 – Respiratory muscles and lung function: from healthy subjects to patients Year: 2018 Rate of FEV1 decline by FEV1 percent predicted in UPLIFT® and TIOSPIR® Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Can we predict change in FEV1 (decliners and non-decliners) in ex-smokers with COPD? Source: Eur Respir J 2005; 26: Suppl. 49, 517s Year: 2005 Individual decline of FEV1 show diversity in COPD Source: Annual Congress 2012 - Environmental exposure and other risk factors for airway diseases Year: 2012 Sputum biomarkers of inflammation in smokers and subjects with COPD Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases Year: 2013 Osteoprotogerin plasma concentrations is correlate with forced expiratory volume at 1 second (FEV1) in patients with COPD Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases Year: 2013 ADAM33 SNPs are associated with excess FEV1 decline in severe early onset COPD Source: Eur Respir J 2006; 28: Suppl. 50, 582s Year: 2006 Mathematical model to predict the risk of future exacerbations in non-smoking patients with COPD Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016 Laboratory and clinical parameters in predicting risk of future exacerbations in both non-smoking and smoking COPD patients Source: International Congress 2014 – Systemic biomarkers for airway diseases Year: 2014 Decline in FEV1 is faster with frequent exacerbations of COPD Source: Eur Respir J 2001; 18: Suppl. 33, 153s Year: 2001 Estimating lung function decline and the effect of smoking in COPD patients Source: Eur Respir J 2002; 20: Suppl. 38, 578s Year: 2002 Intermediate and severe α1-antitrypsin deficiency: influence on plasma α1-antitrypsin, FEV1 and risk of COPD. Three meta-anlyses Source: Eur Respir J 2002; 20: Suppl. 38, 513s Year: 2002 Comparison of breath VOCs collected from controls, healthy smokers, smokers with COPD, and ex-smokers with COPD at two sites Source: International Congress 2015 – Exhaled biomarkers in children and adults with airways disease Year: 2015